Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12,412 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of Body Mass Index on Outcomes in the Edoxaban Versus Warfarin Therapy Groups in Patients Underwent Cardioversion of Atrial Fibrillation (from ENSURE-AF).
Lip GYH, Merino JL, Banach M, de Groot JR, Maier LS, Themistoclakis S, Boriani G, Jin J, Melino M, Winters SM, Goette A. Lip GYH, et al. Among authors: jin j. Am J Cardiol. 2019 Feb 15;123(4):592-597. doi: 10.1016/j.amjcard.2018.11.019. Epub 2018 Nov 24. Am J Cardiol. 2019. PMID: 30527775 Clinical Trial.
Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial.
Kozieł M, Al-Saady N, Hjortshøj SP, Goudev A, Huber K, Cohen A, Jin J, Melino M, Winters SM, Goette A, Lip GYH. Kozieł M, et al. Among authors: jin j. Clin Res Cardiol. 2020 Aug;109(8):1018-1024. doi: 10.1007/s00392-019-01594-9. Epub 2020 Jan 8. Clin Res Cardiol. 2020. PMID: 31915996 Free PMC article. Clinical Trial.
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
Van Mieghem NM, Unverdorben M, Hengstenberg C, Möllmann H, Mehran R, López-Otero D, Nombela-Franco L, Moreno R, Nordbeck P, Thiele H, Lang I, Zamorano JL, Shawl F, Yamamoto M, Watanabe Y, Hayashida K, Hambrecht R, Meincke F, Vranckx P, Jin J, Boersma E, Rodés-Cabau J, Ohlmann P, Capranzano P, Kim HS, Pilgrim T, Anderson R, Baber U, Duggal A, Laeis P, Lanz H, Chen C, Valgimigli M, Veltkamp R, Saito S, Dangas GD; ENVISAGE-TAVI AF Investigators. Van Mieghem NM, et al. Among authors: jin j. N Engl J Med. 2021 Dec 2;385(23):2150-2160. doi: 10.1056/NEJMoa2111016. Epub 2021 Aug 28. N Engl J Med. 2021. PMID: 34449183 Clinical Trial.
Edoxaban vs. Vitamin K Antagonist for Atrial Fibrillation After Transcatheter Aortic Valve Replacement in Japanese Patients　- A Subanalysis of the ENVISAGE-TAVI AF Trial.
Watanabe Y, Hayashida K, Yamamoto M, Yamanaka F, Yamasaki K, Naganuma T, Ohno Y, Yamawaki M, Morioka N, Mizutani K, Tada N, Ueno H, Nishina H, Izumo M, Nakajima Y, Ando K, Takagi K, Kimura T, Sugio K, Dangas G, Van Mieghem NM, Hengstenberg C, Chen C, Jin J, Unverdorben M, Saito S. Watanabe Y, et al. Among authors: jin j. Circ J. 2022 Oct 25;86(11):1756-1763. doi: 10.1253/circj.CJ-22-0093. Epub 2022 Aug 11. Circ J. 2022. PMID: 35965066 Free article. Clinical Trial.
12,412 results
You have reached the last available page of results. Please see the User Guide for more information.